RCKTW · Insider Trading
Rocket Pharmaceuticals, Inc. Warrant
Every open-market purchase and sale reported by RCKTW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-28 | John Militello | See Remarks | MIXED | −121,694 deriv. | — |
| 2026-05-26 | Gaurav Shah | CEO | MIXED | +20,806 | −$42.50K |
| 2026-05-21 | John Militello | See Remarks | Sell | −384 | −$1.16K |
| 2026-05-21 | Martin Wilson | General Counsel | Sell | −662 | −$2.00K |
| 2026-05-21 | Gaurav Shah | CEO | Sell | −2,409 | −$7.26K |
| 2026-05-14 | John Militello | See Remarks | Sell | −855 | −$3.08K |
| 2026-05-14 | Martin Wilson | General Counsel | Sell | −3,361 | −$12.12K |
| 2026-05-14 | Gaurav Shah | CEO | Sell | −2,728 | −$9.84K |
| 2026-05-11 | Sarbani Chaudhuri | See Remarks | Sell | −17,650 | −$67.74K |
| 2026-02-20 | John Militello | See Remarks | Sell | −1,157 | −$3.86K |
| 2026-02-20 | Gaurav Shah | CEO | Sell | −5,990 | −$19.99K |
| 2026-02-20 | Martin Wilson | General Counsel | Sell | −1,376 | −$4.59K |
| 2026-02-18 | John Militello | See Remarks | Sell | −3,726 | −$12.34K |
| 2026-02-18 | Martin Wilson | General Counsel | Sell | −12,253 | −$40.58K |
| 2026-02-18 | Gaurav Shah | CEO | Sell | −12,279 | −$40.67K |
| 2026-02-13 | John Militello | See Remarks | A | +29,982 | — |
| 2026-02-13 | Martin Wilson | General Counsel | A | +311,813 | — |
| 2026-02-13 | Gaurav Shah | CEO | A | +286,028 | — |
| 2026-02-13 | Christopher James Stevens | Chief Operating Officer | A | +61,963 | — |
| 2026-02-13 | Syed Ali-aamir Rizvi | Chief Medical Officer | A | +61,963 | — |
| 2026-02-13 | Sarbani Chaudhuri | See Remarks | A | +125,924 | — |
| 2026-01-06 | Elisabeth Bjork | Director | Buy | +10,000 | +$34.40K |
| 2025-11-20 | Martin Wilson | General Counsel | Sell | −1,646 | −$4.91K |
| 2025-11-20 | John Militello | See Remarks | Sell | −1,086 | −$3.24K |
| 2025-11-20 | Jonathan David Schwartz | See Remarks | Sell | −2,545 | −$7.59K |
| 2025-11-20 | Gaurav Shah | CEO | Sell | −6,276 | −$18.72K |
| 2025-11-10 | Martin Wilson | General Counsel | A | +100,000 | — |
| 2025-10-16 | John Militello | See Remarks | Sell | −28,918 | −$114.58K |
| 2025-10-08 | Syed Ali-aamir Rizvi | Chief Medical Officer | A | +345,911 | — |
| 2025-10-03 | Peter Fong | Director | A | +53,333 | — |
| 2025-09-23 | RTW INVESTMENTS, LP | Director | MIXED | — | +$38.45M |
| 2025-09-09 | Martin Wilson | General Counsel | A | +150,000 | — |
| 2025-09-09 | Jonathan David Schwartz | See Remarks | A | +80,000 | — |
| 2025-09-09 | John Militello | See Remarks | A | +40,000 | — |
| 2025-08-27 | Elisabeth Bjork | Director | Buy | +10,000 | +$34.10K |
| 2025-08-20 | John Militello | See Remarks | Sell | −1,060 | −$3.22K |
| 2025-08-20 | Martin Wilson | General Counsel | Sell | −1,592 | −$4.84K |
| 2025-08-20 | Gaurav Shah | CEO | F | −2,234 | −$6.81K |
| 2025-08-20 | Jonathan David Schwartz | See Remarks | Sell | −2,485 | −$7.56K |
| 2025-08-18 | Martin Wilson | General Counsel | Sell | −12,109 | −$36.56K |
| 2025-08-18 | John Militello | See Remarks | Sell | −7,043 | −$21.26K |
| 2025-08-18 | Jonathan David Schwartz | See Remarks | Sell | −11,161 | −$33.70K |
| 2025-08-06 | Christopher James Stevens | Chief Operating Officer | A | +407,166 | — |
| 2025-07-18 | Mikael Dolsten | Director | A | +30,000 | — |
| 2025-07-18 | Carsten Boess | Director | A | +30,000 | — |
| 2025-07-18 | Elisabeth Bjork | Director | A | +30,000 | — |
| 2025-07-18 | Piratip Pratumsuwan | Director | A | +30,000 | — |
| 2025-07-18 | David P Southwell | Director | A | +30,000 | — |
| 2025-07-18 | Roderick Wong | Director | A | +47,667 | — |
| 2025-07-18 | Fady Ibraham Malik | Director | A | +30,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| RTW INVESTMENTS, LP | Director | 18,236,124 | $36.47K |
| Roderick Wong | Director | 18,236,124 | $36.47K |
| Gaurav Shah | CEO | 1,467,962 | $2.94K |
| Gotham Makker | Director | 1,036,846 | $2.07K |
| Martin Wilson | General Counsel | 677,977 | $1.36K |
| Kinnari Patel | See Remarks | 573,628 | $1.15K |
| Christopher James Stevens | Chief Operating Officer | 469,129 | $938 |
| Syed Ali-aamir Rizvi | Chief Medical Officer | 407,874 | $816 |
| Jonathan David Schwartz | See Remarks | 299,064 | $598 |
| Sarbani Chaudhuri | See Remarks | 267,510 | $535 |
| David P Southwell | Director | 144,784 | $290 |
| Aaron Ondrey | Chief Financial Officer | 128,173 | $256 |
| John Militello | See Remarks | 89,780 | $180 |
| Pedro P Granadillo | Director | 54,734 | $109 |
| Peter Fong | Director | 53,333 | $107 |
| Elisabeth Bjork | Director | 50,000 | $100 |
| Mikael Dolsten | Director | 44,220 | $88 |
| Fady Ibraham Malik | Director | 30,000 | $60 |
| Carsten Boess | Director | 30,000 | $60 |
| Piratip Pratumsuwan | Director | 30,000 | $60 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RCKTW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.